CTIC Share Price

Open 3.94 Change Price %
High 4.04 1 Day 0.07 1.79
Low 3.94 1 Week -0.09 -2.21
Close 3.98 1 Month -0.32 -7.44
Volume 30619 1 Year 3.46 665.38
52 Week High 6.48
52 Week Low 0.31
CTIC Important Levels
Resistance 2 4.07
Resistance 1 4.03
Pivot 3.99
Support 1 3.93
Support 2 3.89
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
SIRI 5.13 1.18%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
CYTR 0.83 36.07%
SUSQ 14.20 -0.77%
MU 26.57 -2.75%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
CPSL 0.09 50.00%
LOCM 0.09 50.00%
RITT 0.03 50.00%
OPTT 2.74 49.73%
CYTR 0.83 36.07%
WRES 0.09 28.57%
BSDM 0.62 26.53%
ATRM 1.89 26.00%
SNTA 0.34 25.93%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

Cell Therapeutics, Inc. (NASDAQ: CTIC)

CTIC Technical Analysis 2
As on 24th Apr 2017 CTIC Share Price closed @ 3.98 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.75 & Strong Sell for SHORT-TERM with Stoploss of 4.32 we also expect STOCK to react on Following IMPORTANT LEVELS.
CTIC Target for April
1st Target up-side 4.47
2nd Target up-side 4.66
3rd Target up-side 4.85
1st Target down-side 3.93
2nd Target down-side 3.74
3rd Target down-side 3.55
CTIC Other Details
Segment EQ
Market Capital 134819600.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.celltherapeutics.com
CTIC Address
CTIC
3101 Western Avenue
Suite 600
Seattle, WA 98121
United States
Phone: 206-282-7100
Fax: 206-284-6206
CTIC Latest News
Interactive Technical Analysis Chart Cell Therapeutics, Inc. ( CTIC NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Cell Therapeutics, Inc.
CTIC Business Profile
Cell Therapeutics, Inc. (CTI) is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic ways to treats cancer. The Company is concentrating its efforts on treatments that target blood-related cancers where there is an unmet medical need. The Company is primarily focused on commercializing PIXUVRI (pixantrone) in the European Union for multiplies relapsed or refractory aggressive non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial of pacritinib for the treatment of myelofibrosis. PIXUVRI is a novel aza-anthracenedione derivative that is structurally related to anthracyclines and anthracenediones, but does not appear to be associated with the same level of cardiotoxic effects.